ATE489105T1 - Faktor ixa zur behandlung von blutungsstörungen - Google Patents

Faktor ixa zur behandlung von blutungsstörungen

Info

Publication number
ATE489105T1
ATE489105T1 AT05724134T AT05724134T ATE489105T1 AT E489105 T1 ATE489105 T1 AT E489105T1 AT 05724134 T AT05724134 T AT 05724134T AT 05724134 T AT05724134 T AT 05724134T AT E489105 T1 ATE489105 T1 AT E489105T1
Authority
AT
Austria
Prior art keywords
factor ixa
bleeding disorders
treatment
factor
subject
Prior art date
Application number
AT05724134T
Other languages
English (en)
Inventor
Shane Donovan
Donald Baker
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Application granted granted Critical
Publication of ATE489105T1 publication Critical patent/ATE489105T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT05724134T 2004-03-19 2005-02-28 Faktor ixa zur behandlung von blutungsstörungen ATE489105T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55472604P 2004-03-19 2004-03-19
PCT/US2005/006527 WO2005094873A1 (en) 2004-03-19 2005-02-28 Factor ixa for the treatment of bleeding disorders

Publications (1)

Publication Number Publication Date
ATE489105T1 true ATE489105T1 (de) 2010-12-15

Family

ID=34961495

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05724134T ATE489105T1 (de) 2004-03-19 2005-02-28 Faktor ixa zur behandlung von blutungsstörungen

Country Status (9)

Country Link
US (2) US7425539B2 (de)
EP (1) EP1755652B1 (de)
JP (2) JP5037331B2 (de)
AT (1) ATE489105T1 (de)
AU (1) AU2005228945B2 (de)
CA (1) CA2557061C (de)
DE (1) DE602005024955D1 (de)
ES (1) ES2357132T3 (de)
WO (1) WO2005094873A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005024955D1 (de) * 2004-03-19 2011-01-05 Baxter Healthcare Sa Faktor ixa zur behandlung von blutungsstörungen
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US8304386B2 (en) * 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US7553941B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
JP2015520128A (ja) 2012-04-19 2015-07-16 オプコ バイオロジクス リミテッド 長時間作用性オキシントモジュリン変異体とその作製方法
ES2882890T3 (es) 2012-11-20 2021-12-03 Opko Biologics Ltd Método para aumentar el volumen hidrodinámico de polipéptidos mediante la unión a péptidos carboxi terminales de la gonadotrofina
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
WO2016092550A2 (en) 2014-12-10 2016-06-16 Opko Biologics Ltd. Methods of producing long acting ctp-modified polypeptides
FR3032621A1 (fr) 2015-02-13 2016-08-19 Lab Francais Du Fractionnement Colle biologique et son utilisation comme medicament
JP6698102B2 (ja) * 2015-04-17 2020-05-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 凝固因子と多重特異的抗体を用いた併用療法
EP3988113A1 (de) 2015-06-19 2022-04-27 OPKO Biologics Ltd. Gerinnungsfaktoren mit langzeitwirkung und verfahren zur herstellung davon
US20180369346A1 (en) * 2016-01-07 2018-12-27 Eio Biomedical Ltd. Methods, compositions and kits for reducing tissue adhesions
BR112019000610A2 (pt) 2016-07-11 2019-07-02 Opko Biologics Ltd fator vii de coagulação de longa ação e métodos de produção do mesmo
CN107758662B (zh) * 2017-10-10 2019-08-20 中国石油大学(华东) 一种磷酸法活性炭活化时间的确定方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560475A (en) * 1969-06-19 1971-02-02 Baxter Laboratories Inc Prothrombin complex prepared by precipitation with polyethylene glycol
US4286056A (en) 1980-01-28 1981-08-25 Baxter Travenol Laboratories, Inc. Method for making therapeutic enzyme compositions
US4357321A (en) * 1980-01-28 1982-11-02 Baxter Travenol Laboratories, Inc. Method and composition for treating clotting factor inhibitors
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
AU5864086A (en) 1985-04-22 1986-11-18 Genetics Institute Inc. High yield production of active factor ix
ES2045167T5 (es) 1987-10-23 1996-07-01 Centre Regional De Transfusion Preparacion de concentrado de factor ix humano de elevada pureza y de otras proteinas plasmaticas.
US5583107A (en) * 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US20040072757A1 (en) 1990-09-04 2004-04-15 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
GB9501040D0 (en) 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
DE19506633A1 (de) 1995-02-25 1996-08-29 Octapharma Ag Verfahren zur Herstellung von Faktor IX aus biologischen Quellen
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
PT2193809E (pt) 1999-02-22 2015-08-24 Baxter Int Formulações de fator viii livres de albumina
EP1048736A1 (de) 1999-04-27 2000-11-02 Aventis Behring Gesellschaft mit beschränkter Haftung DNA-Konstrukt für die Gewebespezifischen Expression eines Blutkoagulationsfaktors
US6441144B1 (en) * 1999-05-20 2002-08-27 Alpha Therapeutic Corporation Method for repairing dual virally inactivated immune globulin for intravenous administration
US6624289B1 (en) * 1999-06-16 2003-09-23 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
WO2001047510A2 (en) * 1999-12-29 2001-07-05 Glaxo Group Limited Methods and compositions related to modulators of annexin and cartilage homeostasis
DK1266006T3 (da) 2000-03-22 2006-01-16 Octagene Gmbh Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
US20030203845A1 (en) 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
US7015193B2 (en) 2001-04-20 2006-03-21 University Of Vermont Compositions and methods to control bleeding
US7977460B2 (en) * 2003-05-19 2011-07-12 National Institute For Biological Standards And Control Compositions comprising coagulation factors IXA and VIII for the treatment of haemophilia A or B
DE602005024955D1 (de) * 2004-03-19 2011-01-05 Baxter Healthcare Sa Faktor ixa zur behandlung von blutungsstörungen

Also Published As

Publication number Publication date
US7767647B2 (en) 2010-08-03
DE602005024955D1 (de) 2011-01-05
CA2557061C (en) 2013-08-20
JP2007529518A (ja) 2007-10-25
CA2557061A1 (en) 2005-10-13
JP2012126743A (ja) 2012-07-05
AU2005228945A1 (en) 2005-10-13
US20050209149A1 (en) 2005-09-22
EP1755652A1 (de) 2007-02-28
JP5037331B2 (ja) 2012-09-26
EP1755652B1 (de) 2010-11-24
HK1102366A1 (en) 2007-11-16
US7425539B2 (en) 2008-09-16
US20090069543A1 (en) 2009-03-12
ES2357132T3 (es) 2011-04-19
AU2005228945B2 (en) 2010-09-30
WO2005094873A1 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
ATE489105T1 (de) Faktor ixa zur behandlung von blutungsstörungen
EA200401525A1 (ru) Способы лечения гепатита (варианты )
ATE296094T1 (de) Stickstoffmonoxid bildende zusammensetzungen zur behandlung von nagelbettinfektionen
TW200612892A (en) Novel compounds
DE602006016760D1 (de) Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen
TW200510416A (en) P38 inhibitors and methods of use thereof
DE602004018788D1 (de) Faktor-ixa-spezifische antikörper, die faktor-viiia-ähnliche wirkung zeigen
UA88645C2 (ru) Гетероарильные соединения как бета-миметики для лечения заболеваний дыхательных путей
ATE399165T1 (de) Chinolinverbindungen und deren verwendungen
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
DE502005008058D1 (de) Gesättigte und ungesättigte 3-pyridyl-benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen
ATE542536T1 (de) 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen
DE602005026276D1 (de) Myricitrin verbindungen zur behandlung von schlafstörungen
ATE423110T1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
DE502007002353D1 (de) Verfahren zur herstellung von cyclischen ketonen
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
ATE373014T1 (de) Einen nanofiltrationsschritt umfassendes verfahren zur aufreinigung von albumin, lösung und zusammensetzung zur therapeutischen anwendung,die dieses enthalten
DE60214207D1 (de) Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis
ATE549023T1 (de) Formulierungen mit jorumycin-, renieramycin-, safracin- oder saframycin-verwandten verbindungen und einen disaccharide zur behandlung von proliferativen erkrankungen
DE602005020113D1 (de) Verfahren zur behandlung von akuten rhinosinusitis
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
ATE397924T1 (de) Satraplatin zur behandlung von resistenten oder refrkatären tumoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1755652

Country of ref document: EP